Skip to search formSkip to main contentSkip to account menu

Mycobutin

Known as: Ansatipine, Pfizer Brand of Rifabutin, Rifabutin Pfizer Brand 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (5)

AnsamycinsAntibioticsAntibiotics, AntitubercularAntitubercular Agents

Narrower (1)

LM 565

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Olfactory disturbance related to pyrazinamide.
  • Cy TsouJ. Chien
  • QJM : monthly journal of the Association of…
  • 2014
  • Corpus ID: 27695998
### Learning Point for Clinicians Pyrazinamide could induce smelling disturbance. The severity is dose-dependent, and it is… 
2011
2011
Immunomodulators in combined therapy of patients with chronic hepatitis
The efficacy of the use of triple schemes in combined therapy of chronic virus hepatitis was estimated and its safety was… 
2008
2008
[Drug sensitivity in Mycobacterium tuberculosis versus its viability, cytotoxicity, genotype, and the course of the process in patients with pulmonary tuberculosis].
The authors studied drug sensitivity, mutations in the katG, in-hA, alpC, rpoB genes, virulence via the cytotoxicity test on THP… 
1994
1994
Ansatipine®: seul traitement prophylactique disponible pour les infections opportunistes à MAC au cours du SIDA : Conférences: une nouvelle prophylaxie dans le SIDA: Ansatipine®
1994
1994
[Prevention of MAI infections in AIDS with Ansatipine: experience at a hospital. From an interview with Dr. Jean-Luc Meynard].
Nowadays, infections by the Mycobacterium avium complex (MAC) have become amongst the most frequent of the opportunistic… 
1994
1994
[The stakes in preventing opportunistic MAI infections in AIDS. From an interview with Dr. Patrick Philibert].
Development of HIV infection is littered with many pathological episodes of which the physical and psychological repercussions on… 
1994
1994
[Ansatipine: only preventive treatment available for opportunistic MAI infections in AIDS. From an interview with Dr. Agnes Mignon].
Ansatipine, the international name of which is rifabutine, is a new specialty that was licensed in February 1993 and marketed in… 
1994
1994
[Opportunistic infections in AIDS: the benefits of an "umbrella strategy." From an interview with Professor Willy Rozenbaum].
Availability to practitioners of a treatment for infections by atypical mycobacteria by Ansatipine should produce a reduction or… 
1994
1994
[A new prophylactic agent in AIDS: Ansatipine. Disseminated Mycobacterium avium complex infection is now the most frequent of the opportunistic bacterial infections in AIDS].
Otherwise infrequent, infections by non-tuberculous or atypical mycobacteria are now rising in AIDS. Infection with the… 
1994
1994
[Prevention of MAI infections in AIDS with Ansatipine: experience at a hospital. From an interview with Dr. Jean-Luc Meynard].
Nowadays, infections by the Mycobacterium avium complex (MAC) have become amongst the most frequent of the opportunistic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)